Mutations identified in the human multidrug resistance P-glycoprotein 3 (ABCB4) gene in patients with primary hepatolithiasis.

Hepatol Res

Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki 305-8575, Japan.

Published: July 2004

Primary hepatolithiasis (HL), highly prevalent in the Far East, including Japan, is characterized clinically by chronic proliferative cholangitis with frequent recurrences. In HL patients, hepatic hyposecretion of phospholipid due to decreased multidrug resistance P-glycoprotein 3 (MDR3; now referred to as ABCB4) expression levels (Hepatology 2001;33:1194-1205) may contribute to the formation of aggressive ductular lesions through a decreased formation of mixed micelles. However, specified factors underlying the decreased expression levels of MDR3 have not been well defined. To determine whether the decreased MDR3 expression level is associated with the gene mutations, mutation analysis of cDNA of the MDR3 gene with focus on the coding region was performed using liver specimens. Heterozygous mutations were detected in only two of 16 HL patients. By sequence analysis of the gene, a 77-bp deletion at nucleotides 537-613 in exon 7 in transmembrane domain (TM) 3, which results in a frameshift at codon 179 and an early stop codon predicting a truncated protein, was found as a heterozygous mutation in two of the 16 patients. A 1-bp deletion at nucleotide 1015 in exon 10 in TM 6 was found as a heterozygous mutation in one of those two patients, and a 242-bp deletion at nucleotides 2683-2924 in exons 22-23 in TM 11 was found as a heterozygous mutation in the same patient. No other mutations were found in the other 14 patients. In real-time polymerase chain reaction (PCR), no significant difference was found between the mRNA levels of MDR3 in the two HL patients with mutations nor in the other 14 patients without mutations. Immunostaining of MDR3 protein was found in the bile canaliculi of liver sections from the two patients with mutations. The results suggest that in primary HL the decreased transcription levels of MDR3 in the liver are not due to the mutations detected in the coding region of the gene.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hepres.2004.03.002DOI Listing

Publication Analysis

Top Keywords

levels mdr3
12
heterozygous mutation
12
patients mutations
12
patients
9
mutations
8
multidrug resistance
8
resistance p-glycoprotein
8
primary hepatolithiasis
8
expression levels
8
coding region
8

Similar Publications

is an emerging pathogen causing recalcitrant skin infections and exhibiting multiple resistances to azoles and allylamines. Squalene epoxidase mutants often show association with azole resistance. RT-PCR gene expression analysis helps to elucidate the connection between ergosterol biosynthesis regulation and efflux control through the activation of multidrug resistance (MDR) and major facilitator superfamily (MFS1) transporters as well as heat shock proteins (HSP).

View Article and Find Full Text PDF
Article Synopsis
  • A new species in the complex has been identified, showing significant resistance to azole drugs and high mortality in infected individuals, highlighting the need for a detailed understanding of its genome.
  • This study utilized whole-genome sequencing of a strain called PWCAL1 to identify azole resistance genes and analyze its pathogenicity and resistance mechanisms through various databases.
  • The findings revealed that the PWCAL1 genome is 31.3 million base pairs long with over 6,800 predicted coding genes, and several unique genes linked to carbohydrate metabolism and virulence factors were identified, aiding in the understanding of its resistance abilities.
View Article and Find Full Text PDF

Previous research highlighted the involvement of the cannabinoid CB1 receptor in regulating the physiology of hepatocytes and hepatic stellate cells. The inhibition of the CB1 receptor via peripherally restricted CB1 receptor inverse agonist JD5037 has shown promise in inhibiting liver fibrosis in mice treated with CCl4. However, its efficacy in phospholipid transporter-deficiency-induced liver fibrosis remains uncertain.

View Article and Find Full Text PDF

What's new in pediatric genetic cholestatic liver disease: advances in etiology, diagnostics and therapeutic approaches.

Curr Opin Pediatr

October 2024

Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, University of Toronto, Toronto, Canada.

Purpose Of Review: To highlight recent advances in pediatric cholestatic liver disease, including promising novel prognostic markers and new therapies.

Findings: Additional genetic variants associated with the progressive familial intrahepatic cholestasis (PFIC) phenotype and new genetic cholangiopathies, with an emerging role of ciliopathy genes, are increasingly being identified. Genotype severity predicts outcomes in bile salt export pump (BSEP) deficiency, and post-biliary diversion serum bile acid levels significantly affect native liver survival in BSEP and progressive familial intrahepatic cholestasis type 1 (FIC1 deficiency) patients.

View Article and Find Full Text PDF

Background And Aims: We asked if comprehensive bile acid profiling could provide insights into the physiopathology of -mutated patients and evaluated the prognostic value of taurine-conjugated tetrahydroxylated bile acid (tauro-THBA) in cholestasis.

Methods: Serum bile acid profiles were evaluated in 13 -mutated patients with 65 healthy controls by ultra-high-performance liquid chromatography/multiple-reaction monitoring-mass spectrometry (UPLC/MRM-MS). The concentration of tauro-THBA was compared between -mutated patients with different prognoses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!